Brief: Nicox Initiates Phase 2B Trial Of NCX 4251

Nicox SA

15/12/2020 06:36

Dec 15 (Reuters) - Nicox SA  NCOX.PA :
    * INITIATES PHASE 2B TRIAL OF NCX 4251, A POTENTIAL
FIRST-IN-CLASS
TREATMENT FOR BLEPHARITIS
    * MISSISSIPPI PHASE 2B TRIAL WILL EVALUATE ONCE-DAILY DOSED
NCX
4251 0.1% VERSUS PLACEBO IN PATIENTS WITH ACUTE EXACERBATIONS OF
BLEPHARITIS
    * IF PRIMARY ENDPOINT IS MET, TRIAL COULD COUNT AS ONE OF
TWO
PIVOTAL TRIALS REQUIRED BY FDA FOR NDA SUBMISSION IN U.S.
    * TOP-LINE RESULTS EXPECTED IN Q4 2021
    * NCX 4251 HAS FIRST-IN-CLASS POTENTIAL, ADDRESSING UNMET
MEDICAL
NEED OF PATIENTS WITH BLEPHARITIS

Source text for Eikon:  ID:nGNX9qNTpL 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))